Arcturus Therapeutics Holdings Inc (ARCT) saw an uptrend of 9.59% in the recent trading with $21.25 being its most recent. The current price level -9.94% lower than the highest price of $23.59 marked by the stock while trading over the past 52-weeks, whereas it is 164.30% higher than the lowest price of $8.04 the company dropped to over past 52-weeks. The latest news story on ARCT appeared in (Zacks) under the title “Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 6 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Arcturus Therapeutics Holdings Inc Earnings – What Happened With ARCT
Coming around sales and income figures on ARCT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Arcturus Therapeutics Holdings Inc (ARCT) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 74.60% for net revenue.
ARCT – Arcturus Therapeutics Holdings Inc Stock Earnings Estimates
The perspective of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s current quarter earnings identifies that analysts are in consensus over the estimate of -1.02 for stock’s EPS in the current quarter. Arcturus Therapeutics Holdings Inc (ARCT) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 74.60% for net revenue. Company’s EPS for the last quarter was -0.26.
Arcturus Therapeutics Holdings Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 27.15 million. ARCT does have institutional investors; and they hold 95.20% of the stock.
As on 2024-06-30, FEDERATED HERMES, INC. was the top most holder in Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) with an ownership of 4.69 million shares of the company or 17.4067 of the stake worth $114.3 million. The filing also reveals BLACKROCK INC. as the second largest holder in the company with a control over 9.8262 of the outstanding shares. Its stake is worth $64.52 million for having 2.65 million shares in hand.
ARK INVESTMENT MANAGEMENT LLC also came holding a key position in the company during the recent quarter and it now holds 7.2866 of the outstanding shares. With this there are now 206.0 institutions which have possession in ARCT’s shares.
Key Metrics for ARCT
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Arcturus Therapeutics Holdings Inc has a debt to equity ratio of 0.12.
